| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Prepaid research and development expenses | - | 123,116 | ||
| Cash and cash equivalents | 48,493,076 | 159,308,966 | ||
| Short-term investments | 7,223,735 | 31,402,850 | ||
| Trade receivables, net | 158,574,116 | 42,911,634 | ||
| Inventories | 28,916,616 | 9,634,438 | ||
| Prepaid expenses and current assets | 16,327,730 | 4,675,885 | ||
| Total current assets | 259,535,273 | 248,056,889 | ||
| Restricted cash, long-term | - | 105,084 | ||
| Property and equipment, net | 4,347,360 | 1,641,152 | ||
| Other long-term assets (including restricted cash of 988,233 and 105,368 at september 30, 2025, and december 31, 2024) | 22,913,753 | - | ||
| Goodwill | 17,515,265 | - | ||
| Intangible assets, net | 390,011,711 | 1,740,260 | ||
| Other assets | - | 642,066 | ||
| Deferred tax assets | 52,500,000 | - | ||
| Operating lease- right-of-use assets, net | 3,173,567 | 413,652 | ||
| Finance lease- right-of-use assets, net | 864,549 | - | ||
| Total assets | 750,861,478 | 252,599,103 | ||
| Accounts payable | 20,454,367 | 5,815,366 | ||
| Accrued expenses | 109,091,898 | 25,718,305 | ||
| Contingent consideration, short-term | 2,673,933 | - | ||
| Operating lease liability, short-term | 844,431 | 177,172 | ||
| Financing lease liability, short-term | 579,168 | - | ||
| Total current liabilities | 133,643,797 | 31,710,843 | ||
| Deferred tax liability | 144,528,552 | - | ||
| Contingent consideration, net of current portion | 95,591,067 | - | ||
| Operating lease liabilities, net of current | 2,411,243 | 258,073 | ||
| Finance lease liabilities, net of current | 557,413 | - | ||
| Total liabilities | 376,732,072 | 31,968,916 | ||
| Preferred stock - 0.001 par value 2,000,000 shares authorized 91,623 and 136,623 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 92 | 92 | ||
| Common stock - 0.001 par value 160,000,000 shares authorized 78,349,057 and 64,411,295 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 78,350 | 74,621 | ||
| Accumulated other comprehensive gain | 87,640 | 79,435 | ||
| Additional paid-in capital | 564,558,498 | 519,634,193 | ||
| Accumulated deficit | -190,595,174 | -299,158,154 | ||
| Total stockholders equity | 374,129,406 | 220,630,187 | ||
| Total liabilities and stockholders equity | 750,861,478 | 252,599,103 | ||
CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD)